

31<sup>st</sup> May, 2023

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1,  
G Block, BKC, Bandra (E),  
Mumbai 400 051

**Scrip Code: BSE - 524500**

**Scrip Code: NSE - KILITCH**

**Sub: Corrigendum to the outcome of the Board Meeting dated 29<sup>th</sup> May, 2023**

Dear Sir,

This has a reference to the outcome of board meeting dated 29<sup>th</sup> May, 2023 wherein the Board considered and approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31<sup>st</sup> March, 2023.

Post submission of the said outcome to the stock exchanges, an inadvertent error was notice in the amount in consolidated statement of Cash Flow under the head 'Capital expenditure on PPE, CWIP including capital advances' was not captured properly due to link issue.

The revised Consolidated Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2023 is attached herewith.

All other particulars and details remain unchanged.

The corrigendum shall be read with the Outcome of Board meeting dated 29<sup>th</sup> May, 2023.

Request you to kindly take note of the same and acknowledge the receipt.

Thanking You,

Yours faithfully,

For **Kilitch Drugs (India) Limited**

MUKUND  
PRATAPRAI  
MEHTA

Digital signed by MUKUND PRATAPRAI MEHTA  
DN: c=IN, o=PERSONAL,  
ou=PERSONAL, email=prataprai.mehta@kilitch.com,  
serial=202305291145214.000, postalCode=400033,  
st=MAHARASHTRA,  
cn=MUKUND PRATAPRAI MEHTA,  
email=prataprai.mehta@kilitch.com,  
email=202305291145214.000

**Mukund Mehta**  
**Managing Director**  
**DIN: 00147876**



**KILITCH DRUGS (INDIA) LIMITED**  
**STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED 31ST MARCH, 2023**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701  
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com  
 CIN: L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	Three Months Ended			Year Ended	
		31/03/2023	31/12/2022	31/03/2022	31/03/2023	31/03/2022
		Audited	Unaudited	Audited	Audited	Audited
<b>1</b>	<b>Income</b>					
	Net Sales/ Income from operations	4,328.28	2,850.34	3,203.07	11,778.35	10,515.98
	Other Income	143.18	111.30	76.85	459.76	455.90
	<b>Total Income</b>	<b>4,471.46</b>	<b>2,961.64</b>	<b>3,279.92</b>	<b>12,238.11</b>	<b>10,971.88</b>
<b>2</b>	<b>Expenses</b>					
	Cost of Materials Consumed	2,415.23	1,283.39	1,777.46	5,826.62	6,028.55
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(27.49)	28.13	(7.76)	22.68	(4.69)
	Employee Benefit Expenses	216.35	191.45	162.88	746.64	615.45
	Finance Cost	40.73	27.67	17.71	98.53	66.27
	Depreciation and Amortisation Expenses	37.31	37.83	25.88	133.71	96.42
	Export Product Registration/Commission	541.77	215.63	123.03	1,130.42	542.79
	Other Expenses	513.71	710.19	749.82	2,334.65	2,234.27
	<b>Total Expenses</b>	<b>3,737.61</b>	<b>2,494.29</b>	<b>2,849.03</b>	<b>10,293.25</b>	<b>9,579.06</b>
<b>3</b>	<b>Profit / (Loss) before Exceptional items (1-2)</b>	<b>733.85</b>	<b>467.35</b>	<b>430.89</b>	<b>1,944.86</b>	<b>1,392.82</b>
<b>4</b>	Exceptional Items	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from ordinary activities before tax (3+4)</b>	<b>733.85</b>	<b>467.35</b>	<b>430.89</b>	<b>1,944.86</b>	<b>1,392.82</b>
<b>6</b>	Less: Tax Expenses:-					
	Current Tax - [Refer Note No. 4]	204.00	144.50	143.05	419.76	363.37
	Deferred Tax	17.05	(70.14)	(14.48)	(46.63)	(23.32)
<b>7</b>	<b>Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)</b>	<b>512.80</b>	<b>392.99</b>	<b>302.32</b>	<b>1,571.73</b>	<b>1,052.77</b>
<b>8</b>	Other Comprehensive Income (after tax)	5.27	40.48	(37.29)	(31.75)	198.15
<b>9</b>	<b>Total Comprehensive Income (after taxes) (7+8)</b>	<b>518.07</b>	<b>433.47</b>	<b>265.03</b>	<b>1,539.98</b>	<b>1,250.92</b>
<b>10</b>	Paid-Up equity share capital (Face Value Rs 10 per share)	1,558.23	1,558.23	1,558.23	1,558.23	1,558.23
<b>11</b>	Other Equity				18,034.86	16,244.89
<b>12</b>	<b>Earning per share (not annualised)</b>					
	(a) Basic	3.29	2.53	1.94	10.09	6.76
	(b) Diluted	3.29	2.53	1.94	10.09	6.76

**Notes:**

- The above Audited Financial Results of the Company for the quarter and year ended 31st March, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th May, 2023.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The Current Tax for the year ended 31st March, 2023 is net off the Tax adjustments of earlier years aggregating to Rs. (124.24) Lakhs.  
The figures for the quarter ended 31st March, 2023 and 31st March, 2022 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2023 and 31st March, 2022 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
- The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable with the current periods.

For and on behalf of the Board of Directors

*Mukund Mehta*

Mukund Mehta  
 Managing Director  
 DIN: 00147876

Place: Mumbai  
 Dated: 29th May, 2023



**KILITCH DRUGS (INDIA) LIMITED**  
AUDITED STANDALONE BALANCE SHEET AS AT 31ST MARCH, 2023

(Rs. in Lakhs)

Particulars	As at 31st March, 2023	As at 31st March, 2022
	Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
- Property, Plant and Equipment	1,481.61	1,394.83
- Capital work-in-progress	131.15	-
- Other Intangible Assets	26.32	23.41
<b>Financial assets</b>		
- Investments	7,109.75	7,014.88
- Loans/Advances	4,817.14	4,659.80
- Other Financial Assets	1.79	213.59
Deferred tax assets (Net)	197.38	150.76
(A)	<b>13,765.14</b>	<b>13,457.27</b>
<b>Current Assets</b>		
- Inventories	204.46	500.02
<b>Financial assets</b>		
- Investments	3,919.68	4,723.42
- Trade Receivables	5,310.22	4,142.19
- Cash & Cash Equivalents	1,783.58	244.96
- Other Bank Balances	13.39	-
- Other Financial Assets	2.15	2.02
Other Current Assets	243.17	159.38
(B)	<b>11,476.65</b>	<b>9,771.99</b>
<b>TOTAL ASSETS (A + B)</b>	<b>25,241.79</b>	<b>23,229.26</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
- Equity Share Capital	1,558.23	1,558.23
- Other Equity	18,034.86	16,244.89
(A)	<b>19,593.09</b>	<b>17,803.12</b>
<b>Liabilities</b>		
<b>Non-Current liabilities</b>		
- Provisions	6.83	27.54
(B)	<b>6.83</b>	<b>27.54</b>
<b>Current liabilities</b>		
<b>Financial Liabilities</b>		
- Borrowings	2,186.42	2,033.48
- Trade Payables		
Micro and Small Enterprises		
Others	2,883.64	2,776.84
- Other Financial Liabilities	3.87	3.88
Provisions	151.27	100.88
Current Tax Liabilities (Net)	403.89	439.62
Other Current Liabilities	12.78	43.90
(C)	<b>5,641.87</b>	<b>5,398.60</b>
<b>TOTAL EQUITY AND LIABILITIES (A+B+C)</b>	<b>25,241.79</b>	<b>23,229.26</b>

For and on behalf of the Board of Directors

*Mukund Mehta*

Mukund Mehta  
Managing Director  
DIN: 00147876



Place : Mumbai  
Dated : 29th May, 2023



**KILITCH DRUGS (INDIA) LIMITED**  
**AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2023**

(Rs. in Lakhs)

Particulars	Year Ended 31st March, 2023		Year Ended 31st March 2022	
	Audited		Audited	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit / (Loss) before extraordinary items and tax		1,944.86		1,392.82
<i>Adjustments for:</i>				
Depreciation and amortization				
Interest income	133.71		96.42	
Dividend income	(198.91)		(195.96)	
(Profit)/Loss on sale of Investments	(0.87)		(3.05)	
Provision for Gratuity & Leave Encashment	(98.80)		(135.92)	
Interest Expenses	0.00		3.41	
Bad Debts / Provision for Doubtful Debts	98.53		66.27	
(Profit) / Loss from Investment in Partnership Firm	313.88		106.46	
Net unrealised exchange (gain) / loss	0.19		0.20	
Net unrealised exchange (gain) / loss	(52.58)		71.76	9.59
<b>Operating profit / (loss) before working capital changes</b>		195.15		9.59
<i>Changes in working capital:</i>				
<i>Operating Assets:</i>				
Inventories				
Trade receivables	295.56		(141.41)	
Other current assets	(1,429.35)		(2,028.59)	
Deposits & advances	(83.79)		146.92	
Other financial assets	(17.05)		(2.16)	
<i>Operating Liabilities:</i>				
Trade payables				
Other current liabilities	106.80		1,352.51	
Provisions	(31.10)		32.40	
Provisions	61.72	(1,097.21)	12.13	(628.25)
<b>Gross cash flow from / (used in) operating activities</b>		2,140.01		1,402.41
Direct Taxes (Paid) /refunded		1,042.80		774.16
		(433.07)		(253.66)
<b>Net cash flow from / (used in) operating activities (A)</b>		609.73		520.50
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Purchases of Property, Plant & Equipment and CWIP	(354.56)		(820.18)	
Loans/Advances to related Parties	(140.29)		(257.33)	
Proceeds/(Purchases) [Net] of Current Investments	816.34		(687.48)	
Proceeds/(Purchases) [Net] of Non-Current Investments	(95.06)		(5.03)	
Movement in other Bank balances	198.41		(37.25)	
Interest received	198.77		195.96	
Dividend received	0.87		3.05	
		624.48		(1,608.26)
		624.48		(1,608.26)
<b>Net cash flow from / (used in) investing activities (B)</b>		624.48		(1,608.26)
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from Shares issued [incl. ESOPs]			8.79	
Application money received against Share Warrants			250.00	
Proceeds from Borrowings (Net of Repayments)	250.00		562.81	
Interest paid	152.94		(66.27)	
Interest paid	(98.53)			
<b>Net cash flow from / (used in) financing activities (C)</b>		304.41		755.33
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		1,538.62		(332.43)
Cash and cash equivalents at the beginning of the year		244.96		577.39
<b>Cash and cash equivalents at the end of the year</b>		1,783.58		244.96
<b>Cash and cash equivalents at the end of the year *</b>				
* Comprises:				
(a) Cash on hand				
(b) Balances with banks		1.02		0.45
(i) In current accounts		1,778.70		240.63
(ii) In earmarked accounts		3.86		3.88
		1,783.58		244.96

Place : Mumbai  
Dated : 29th May, 2023



*Mukund Mehta*

Mukund Mehta  
Managing Director  
DIN: 00147876



**KILITCH DRUGS (INDIA) LIMITED**  
**STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED 31ST MARCH, 2023**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701  
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com  
 CIN: L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED				
		Three Months Ended			Year Ended	
		31-03-23 Audited (Refer Note 5)	31-12-22 Unaudited	31-03-22 Audited (Refer Note 5)	31-03-23 Audited	31-03-22 Audited
<b>1</b>	<b>Income</b>					
	Net Sales/Income from Operations	4,547.70	2,997.23	3,660.75	13,959.90	11,423.42
	Other Income	102.04	68.66	37.83	291.80	290.93
	<b>Total Income</b>	<b>4,649.74</b>	<b>3,065.89</b>	<b>3,698.58</b>	<b>14,251.70</b>	<b>11,714.35</b>
<b>2</b>	<b>Expenses</b>					
	Cost of Materials Consumed	2,582.08	1,336.64	2,055.88	7,453.23	6,548.03
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(27.50)	28.13	(7.75)	22.67	(4.69)
	Employee Benefit Expenses	289.06	297.76	163.57	1,173.36	618.31
	Finance Cost	120.69	128.85	71.28	491.89	119.84
	Depreciation and Amortisation Expenses	91.43	92.71	112.69	355.06	246.56
	Export Product Registration/Commission	542.84	218.76	128.37	1,142.40	548.13
	Other expenses	539.90	717.92	815.98	2,411.66	2,676.73
	<b>Total Expenses</b>	<b>4,138.50</b>	<b>2,820.77</b>	<b>3,340.02</b>	<b>13,050.27</b>	<b>10,752.91</b>
<b>3</b>	<b>Profit before Exceptional items (1-2)</b>	<b>511.24</b>	<b>245.12</b>	<b>358.56</b>	<b>1,201.43</b>	<b>961.44</b>
<b>4</b>	<b>Exceptional Items</b>	-	-	-	-	-
<b>5</b>	<b>Profit from ordinary activities before tax (3+4)</b>	<b>511.24</b>	<b>245.12</b>	<b>358.56</b>	<b>1,201.43</b>	<b>961.44</b>
<b>6</b>	<b>Less : Tax Expenses</b>					
	Current Income Tax	204.00	144.50	143.05	419.76	363.37
	Deferred Tax	17.09	(70.19)	(14.47)	(46.60)	(23.30)
<b>7</b>	<b>Profit after tax for the period from continuing operations (5-6)</b>	<b>290.15</b>	<b>170.81</b>	<b>229.98</b>	<b>828.27</b>	<b>621.37</b>
	Add/(Less): Share in Profits/(Loss) of Associates	-	-	-	-	-
<b>8</b>	<b>Net Profit/(Loss) After Tax &amp; Share in Profits/(Loss) of Associates</b>	<b>290.15</b>	<b>170.81</b>	<b>229.98</b>	<b>828.27</b>	<b>621.37</b>
<b>9</b>	<b>Other Comprehensive Income (after Tax)</b>	<b>5.27</b>	<b>40.48</b>	<b>(37.29)</b>	<b>(31.75)</b>	<b>198.15</b>
<b>10</b>	<b>Total Comprehensive Income (after taxes) (8+9)</b>	<b>295.42</b>	<b>211.29</b>	<b>192.69</b>	<b>796.52</b>	<b>819.52</b>
<b>11</b>	<b>Net Profit / (Loss) attributable to</b>					
	a) Owner of the Company	356.37	237.07	289.82	1,044.81	736.73
	b) Non Controlling Interest	(66.22)	(66.26)	(59.84)	(216.54)	(115.36)
<b>12</b>	<b>Other Comprehensive Income attributable to</b>					
	a) Owner of the Company	5.27	40.48	(37.29)	(31.75)	198.15
	b) Non Controlling Interest	-	-	-	-	-
<b>13</b>	<b>Total Income attributable to</b>					
	a) Owner of the Company	361.64	277.55	252.53	1,013.06	934.88
	b) Non Controlling Interest	(66.22)	(66.26)	(59.84)	(216.54)	(115.36)
<b>14</b>	<b>Paid-Up equity share capital (Face Value Rs. 10 per share)</b>	<b>1,558.23</b>	<b>1,558.23</b>	<b>1,558.23</b>	<b>1,558.23</b>	<b>1,558.23</b>
<b>15</b>	<b>Other Equity</b>				<b>13,601.49</b>	<b>12,350.41</b>
<b>16</b>	<b>Earning per share (not annualised)</b>					
	(a) Basic	2.29	1.52	1.86	6.71	4.73
	(b) Diluted	2.29	1.52	1.86	6.71	4.73


**Notes:**

- The above audited Consolidated Financial Results of the Company for the quarter and year ended 31st March, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 29th May, 2023.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The Current Tax for the year ended 31st March, 2023 is net off the Tax adjustments of earlier years aggregating to Rs. (124.24) Lakhs.
- The figures for the quarter ended 31st March, 2023 and 31st March, 2022 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2023 and 31st March, 2022 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.  
The figures for the corresponding previous periods have been regrouped/reclassified, wherever necessary, to make them comparable with the current periods.

For and on behalf of the Board of Directors

Mukund P. Mehta  
 Director  
 DIN: 00147876

Place: Mumbai  
 Date: 29th May, 2023




**KILITCH DRUGS (INDIA) LIMITED**  
AUDITED CONSOLIDATED BALANCE SHEET AS AT 31ST MARCH, 2023

(Rs. In Lakhs)

Particulars	As at 31st March, 2023	As at 31st March, 2022
	Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and Equipment	4,373.89	4,324.23
Capital work-in-progress	361.92	316.11
Other Intangible assets	2,048.43	2,129.77
<b>Financial assets</b>		
- Investments	2,265.96	2,393.18
- Loans/Advances	62.06	46.31
- Other Financials Assets	1.79	213.59
Deferred tax assets (Net)	197.77	151.18
<b>(A)</b>	<b>9,311.82</b>	<b>9,574.37</b>
<b>Current assets</b>		
Inventories	204.46	500.02
<b>Financial assets</b>		
- Investments	3,919.68	4,723.42
- Trade and other receivables	5,428.70	4,141.17
- Cash and cash equivalents	1,984.60	1,006.15
- Other Bank Balances	13.39	-
- Other Financials Assets	2.15	2.02
Other current assets	1,087.33	1,037.67
<b>(B)</b>	<b>12,640.31</b>	<b>11,410.45</b>
<b>TOTAL ASSETS (A + B)</b>	<b>21,952.13</b>	<b>20,984.82</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share capital	1,558.23	1,558.23
Other Equity	13,601.49	12,350.41
<b>Equity attributable to the owners</b>	<b>15,159.72</b>	<b>13,908.64</b>
Non-controlling interest	(101.73)	120.72
<b>(A)</b>	<b>15,057.99</b>	<b>14,029.36</b>
<b>Liabilities</b>		
<b>Non - Current Liabilities</b>		
Provisions	6.83	27.54
<b>(B)</b>	<b>6.83</b>	<b>27.54</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
- Borrowings	2,219.35	2,043.18
- Trade Payables		
Micro and Small Enterprises	-	-
Others	4,087.45	4,286.91
- Other financial liabilities	3.87	3.88
Provisions	151.63	100.88
Current tax Liabilities (Net)	403.89	439.62
Other current liabilities	21.12	53.45
<b>(C)</b>	<b>6,887.31</b>	<b>6,927.92</b>
<b>TOTAL EQUITY AND LIABILITIES (A + B)</b>	<b>21,952.13</b>	<b>20,984.82</b>

For and on behalf of the Board of Directors



**Mukund P. Mehta**  
Managing Director  
DIN: 00147876

Place : Mumbai  
Date : 29th May, 2023



**KILITCH DRUGS (INDIA) LIMITED**  
AUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2023

(Rs. In Lakhs)

Particulars	For the Year ended 31st March 2023		For the Year ended 31st March 2022	
	Audited		Audited	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit / (Loss) before extraordinary items and tax		1,201.43		961.44
<i>Adjustments for:</i>				
Depreciation and amortisation	355.06		246.56	
Interest income	(30.17)		(21.91)	
Dividend income	(0.87)		(3.05)	
(Profit)/Loss on sale of Investments	(98.80)		(135.92)	
Share of (Profit) / Loss from Partnership Firm	0.19		0.20	
Provision for Gratuity & Leave Encashment	-		3.41	
Interest Expenses	491.89		119.84	
Bad Debts / Provision for Doubtful Debts	313.88		108.57	
Net unrealised exchange (gain) / loss	(52.58)	978.60	71.76	389.46
<b>Operating profit / (loss) before working capital changes</b>		2,180.03		1,350.90
<i>Changes in working capital:</i>				
<i>Operating Assets:</i>				
Inventories	295.56		(141.41)	
Trade receivables	(1,548.83)		(2,029.66)	
Other financial Assets	-		(0.05)	
Other current assets	(49.66)		(543.74)	
Deposit & Advances	(15.75)		(2.17)	
<i>Operating Liabilities:</i>				
Trade payables	(199.46)		2,271.50	
Other financial liabilities	0.01		-	
Other current liabilities	(32.33)		(83.39)	
Short-term provisions	62.08	(1,488.38)	9.97	(518.96)
Gross cash flow from / (used in) operating activities		691.65		831.94
Direct Taxes (Paid) / refunded		(433.07)		(253.64)
<b>Net cash flow from / (used in) operating activities</b>		258.58		578.30
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on PPE,CWIP including capital advances	(381.19)		(820.18)	
Proceeds (Net) from the sale of Current investments	816.34		(687.48)	
(Purchase)/Sale (Net) of long-term investments:	127.03		-	
Loans / Advances Related Party	-		(5.04)	
Movement in other Bank balance	198.41		(37.25)	
Interest received	30.05		21.86	
Dividend received	0.87		3.05	
		791.50		(1,525.04)
<b>Net cash flow from / (used in) investing activities (B)</b>		791.50		(1,525.04)
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from Shares issued [incl. ESOPs]	-		8.78	
Application money received against Share Warrants	250.00		250.00	
Proceeds from Borrowings (Net of Repayments)	176.17		562.81	
Proceeds from Minorities	(5.91)		1.08	
Interest paid	(491.89)		(119.84)	
		(71.63)		702.83
<b>Net cash flow from / (used in) financing activities (C)</b>		(71.63)		702.83
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		978.45		(243.91)
Cash and cash equivalents at the beginning of the year		1,006.15		1,250.05
<b>Cash and cash equivalents at the end of the year</b>		1,984.60		1,006.15
<b>Cash and cash equivalents at the end of the year *</b>				
* Comprises:				
(a) Cash on hand		1.15		0.58
(b) Balances with banks				
(i) In current accounts		1,979.59		1,001.69
(ii) In earmarked accounts		3.86		3.88
		1,984.60		1,006.15



For and on behalf of the Board of Directors

Mukund P. Mehta  
Mahaging Director

Place : Mumbai  
Date : 29th May, 2023